[HTML][HTML] The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway …
M Harada, J Benito, S Yamamoto, S Kaur, D Arslan… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Mammalian target of rapamycin (mTOR) signaling is a critical pathway in the biology of
acute myeloid leukemia (AML). Proviral integration site for moloney murine leukemia virus …
acute myeloid leukemia (AML). Proviral integration site for moloney murine leukemia virus …
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia
LS Chen, JY Yang, H Liang, JE Cortes… - Leukemia & …, 2016 - Taylor & Francis
Pim kinases phosphorylate and regulate a number of key acute myeloid leukemia (AML) cell
survival proteins, and Pim inhibitors have recently entered clinical trial for hematological …
survival proteins, and Pim inhibitors have recently entered clinical trial for hematological …
[HTML][HTML] A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream
effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute …
effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute …
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
L Willems, N Chapuis, A Puissant, TT Maciel, AS Green… - Leukemia, 2012 - nature.com
The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell
growth and proliferation, and is constitutively activated in primary acute myeloid leukemia …
growth and proliferation, and is constitutively activated in primary acute myeloid leukemia …
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
J Tamburini, N Chapuis, V Bardet… - Blood, The Journal …, 2008 - ashpublications.org
The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently
activated, representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 …
activated, representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 …
[HTML][HTML] MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells
Abstract mTOR activation leads to enhanced survival signaling in acute myeloid leukemia
(AML) cells. The active-site mTOR inhibitors (asTORi) represent a promising new approach …
(AML) cells. The active-site mTOR inhibitors (asTORi) represent a promising new approach …
SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt
H Meng, Y Jin, H Liu, L You, C Yang, X Yang… - Journal of Hematology & …, 2013 - Springer
Background Acute myeloid leukemia (AML) is a heterogeneous disorder with aberrant
regulation of a variety of signal pathways. Therefore, simultaneous targeting of two or even …
regulation of a variety of signal pathways. Therefore, simultaneous targeting of two or even …
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways
K Meja, C Stengel, R Sellar, D Huszar… - British journal of …, 2014 - Wiley Online Library
Summary PIM kinases (PIM1, 2 and 3) are involved in cell proliferation and survival
signalling and are emerging targets for the therapy of various malignancies. We found that a …
signalling and are emerging targets for the therapy of various malignancies. We found that a …
[HTML][HTML] Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
M Colamonici, G Blyth, D Saleiro, A Szilard… - Oncotarget, 2015 - ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) and phosphoinositide-3-kinase (PI3K)
pathways are often aberrantly activated in acute myeloid leukemia (AML) and play critical …
pathways are often aberrantly activated in acute myeloid leukemia (AML) and play critical …
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
C Grimaldi, F Chiarini, G Tabellini, F Ricci, PL Tazzari… - Leukemia, 2012 - nature.com
The mammalian target of rapamycin (mTOR) serine/threonine kinase is the catalytic subunit
of two multi-protein complexes, referred to as mTORC1 and mTORC2. Signaling …
of two multi-protein complexes, referred to as mTORC1 and mTORC2. Signaling …